|
Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies. |
|
|
Consulting or Advisory Role - Eisai |
|
|
Consulting or Advisory Role - Eisai |
|
|
No Relationships to Disclose |
|
|
Leadership - ACORN Research |
Consulting or Advisory Role - Amgen; Eisai; Teva |
Speakers' Bureau - Eisai; Genentech; Novartis |
|
|
|
No Relationships to Disclose |
|
Shannon Leigh Huggins-Puhalla |
Consulting or Advisory Role - Celldex; MedImmune; Pfizer |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - Eisai |
|